SCHEMBL4605322

SCHEMBL4605322

CCC(=O)Nc1ccc(CCc2ccccc2C(F)(F)F)cc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.47
KDM4E B2RXH2 3/20 0.47
GAA P10253 2/20 0.47
POLB P06746 2/20 0.47
PKM P14618 2/20 0.47
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
HDAC1 Q13547 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
KMT2A Q03164 2/20 0.43
FFAR1 O14842 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
METAP2 P50579 2/20 0.43
PLK1 P53350 1/20 0.43
LTC4S Q16873 1/20 0.43
ALDH1A1 P00352 3/20 0.42
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4604157 0.83 AKR1C3 (0.47) KDM4EGAAPOLBPKMAKR1C3
SCHEMBL4604582 0.81 MAOB (0.53) KDM4EGAAPKMAKR1C3AKR1C2
SCHEMBL6105882 0.81 GAA (0.56) KDM4EGAAPOLBAKR1C3AKR1C2
SCHEMBL4605839 0.81 RXRA (0.57) KDM4EGAAPKMAKR1C3AKR1C2
SCHEMBL5712901 0.80 AKR1C3 (0.56) KDM4EGAAPOLBAKR1C3AKR1C2
SCHEMBL27519885 0.76 GRIK1 (0.55) KDM4EGAAPOLBKMT2AHSD17B10
SCHEMBL4604528 0.76 KDM4E (0.70) KDM4EPOLBPKMKMT2AMETAP2
SCHEMBL4605316 0.76 AKR1C3 (0.46) KDM4EGAAPOLBPKMAKR1C3
SCHEMBL4619861 0.76 KDM4E (0.47) KDM4EGAAPKMAKR1C3AKR1C2
SCHEMBL27546648 0.75 GAA (0.65) GAAPOLBKMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1914152-B New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB 2010-06-09 CN disclosed
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
CN-1914152-A New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2007-02-14 CN disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 NR3C2 131/4885KDM4E 2898/4885GAA 864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.